AI-Enabled Early Detection of Cognitive Decline

Qualify patients & measure efficacy of treatment using functional brain activity
Collaborate with us Today

Measuring symptomatic decline is the key to creating effective interventions for neurological disease.

Vision

At Vistim Labs (Vistim) our vision is a new standard of care where patients, clinicians, and researchers can quickly and easily predict possible neurodegenerative disease, enabling opportunities to intervene to save individuals, families, and communities.

Mission

Vistim’s mission is to increase access to care and clinical decision making ability with our proprietary artificial intelligence (AI) platform. Our platform produces meaningful biomarkers of cognitive decline, available for measuring efficacy of treatment and predicting symptomatic onset, using functional brain activity collected via active-paradigm electroencephalography (EEG).

Learn more about our progress

Vistim’s provides highly sensitive prediction of amyloid beta levels in the brain.

We now seek to validate our ability to predict cognitive deficit.

Would you like to publish together as research partners?

Collaborate with us Today

Relevant Press & Publications

VISTIM LABS 1 OF 11 INVITED TO EXCLUSIVE ACCELERATOR, PHARMSTARS

Read more

CEO JAMES HAMET PUBLISHED FOR NOVEL EEG BIOMARKERS OF MENTAL FATIGUE

Read more

THE REASON I FEEL OPTIMISTIC ABOUT THE FUTURE OF ALZHEIMER’S RESEARCH

Read more

CTAD 2021 REFLECTS PROMISING MOVEMENT IN ALZHEIMER’S RESEARCH

Read more